Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report.
10.5125/jkaoms.2013.39.1.9
- Author:
Jeong Keun LEE
1
;
Kyung Wook KIM
;
Jin Young CHOI
;
Seong Yong MOON
;
Su Gwan KIM
;
Chul Hwan KIM
;
Hyeon Min KIM
;
Yong Dae KWON
;
Yong Deok KIM
;
Dong Keun LEE
;
Seung Ki MIN
;
In Sook PARK
;
Young Wook PARK
;
Min Suk KOOK
;
Hong Ju PARK
;
Jin A BAEK
;
Jun Woo PARK
;
Tae Geon KWON
Author Information
1. Board of Bone Bank, Ajou University, Suwon, Korea.
- Publication Type:Original Article
- Keywords:
Bisphosphonate;
Osteonecrosis;
Jaw;
Data collection
- MeSH:
Administration, Intravenous;
Alendronate;
Bisphosphonate-Associated Osteonecrosis of the Jaw;
Data Collection;
Diphosphonates;
Etidronic Acid;
Humans;
Incidence;
Jaw;
Korea;
Osteonecrosis;
Schools, Dental;
Schools, Medical;
Surgery, Oral;
Risedronate Sodium
- From:Journal of the Korean Association of Oral and Maxillofacial Surgeons
2013;39(1):9-13
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVES: Bisphosphonates (BP) are widely used in medicine for inhibiting bone resorption; however bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a major side effect of BP. To date, there have been no specific reports on the incidence of BRONJ among Koreans. This study investigated the preliminary results from a nationwide survey of BRONJ in the Departments of Oral and Maxillofacial Surgery (OMFS) at individual training hospitals. MATERIALS AND METHODS: A total of 15 OMFS departments (10 from dental schools, 4 from medical schools, and 1 from a dental hospital) participated in a multi-centric survey. This study assessed every BRONJ case diagnosed between January 2010 and December 2010. The patient age and BP type were evaluated. RESULTS: A total of 254 BRONJ cases were collected. The majority of BRONJ cases were associated with oral BP therapy, while 21.8% of the cases were associated with intravenous administration. Alendronate was the drug most frequently related to BRONJ (59.2% of cases), followed by risedronate (14.3%) and zolendronate (17.0%). The average age of BRONJ patients was 70.0+/-10.1 years, with a range of 38-88 years of age. With the number of BP patients in Korea reported to be around 600,000 in 2008, the estimated incidence of BRONJ is at least 0.04% or 1 per 2,300 BP patients. CONCLUSION: The results suggest that the estimated incidence of BRONJ in Korea is higher than the incidence of other countries. Future prospective studies should be carried out to investigate the exact epidemiological characteristics of BRONJ in Korea.
